Myoblast Technology Gains Significant Support in CHINA
2012-09-28
It is not surprising that patients worldwide suffering muscular dystrophies and heart failure are contacting Professor Peter K. Law for myoblast treatment. After all, myoblast transfer is the only method which increased the maximum contractile force of Duchenne muscular dystrophy (DMD) patients by 123% at 18 months after cell implantation, and increased the left ventricular ejection fraction of ischemic heart patients by 35% at 12 months postoperatively (Law & Law 2011). These translate into life prolongation, quality-of-life improvement and delay in being wheelchair-bound for the patient.
Ever since the Chairman and the Prime Minister of CHINA honored Professor Law to work in CHINA, myoblast technology has gained significant support, beginning with the top biomedical award of the “3551 Talent Scheme” of the Wuhan East Lake National Innovation Zone, and ending lately with an award of the “CHINA 1000 Plan”. Professor Law’s team has been awarded substantial funds and 45.6 acres of land to build the world’s first headquarter for myoblast manufacture, teaching, research and treatment. This Cell Therapy Institute (CTI) is now producing quality myoblasts suitable for human use.
Prominent professors of different university medical centers have signed up as collaborators. These include Academician Junbo Ge of Shanghai Institute of Cardiovascular Disease, Professor Changsheng Ma of Beijing Anzhen Hospital, President Zhongmin Liu and Professor Huimin Fan of Shanghai East Hospital, Professor Cheng Zhang of Sun Yat-Sen University of Medical Sciences, and Professor Suo Bin Wang of Beijing Xuan Wu Hospital. They will provide clinical care for our muscular dystrophy and heart patients.
Myoblasts are not stem cells. They are differentiated cells developing to become muscle and not other cell type. By definition, stem cell has the potential to differentiate to become two or more cell types.
Throughout published studies of the 280 muscular dystrophy patients and 300 heart patients, myoblast production and implantation were in compliance with Good Manufacturing Practices and Good Clinical Practices. Much of the standards were conceived and instigated by the technology inventor Professor Law who holds worldwide patents on the technology. Published reports provide evidence to indicate that Myoblast Transfer Therapy is safe and efficacious. The Chinese Ministry of Science and Technology, and the Chinese Ministry of Health have promised support to develop the technology unto commercialization so that patients worldwide can receive the treatment they urgently need.
For the many patients who contacted us, please take time to learn about the myoblast technology (Law & Law 2011) and email us your medical records. It is through understanding that you will realize that, in fact, there is only one scientific approach in regenerative medicine for these fatal and debilitating diseases with no known cure, and that is Myoblast Transfer Therapy!
References
Law P K and Law DM. Human myoblast genome therapies and devices in regenerative medicine. Rec Pat Regen Med 2011; 1: 88-117.
